Psychiatrie pro praxi – 3/2019

www.psychiatriepropraxi.cz e25 PŘEHLEDOVÉ ČLÁNKY Depresivní příznaky u jednotlivých neurologických poruch PSYCHIATRIE PRO PRAXI 2012). Dalším tématem je využití antidepresiv v rámci prevence deprese. Jako nejúčinější se jeví podání amiptryptilinu (Burch, 2019). Závěr Tento článek se zabývá jen zlomkem neurologických a psychia- trických poruch. Vzájemnost obou skupin je mnohem širší. Navzdory vysoké frekvenci existuje jen málo informací o etiopatogenezi psy- chických poruch u neurologických pacientů. Stejně tak doposud ne- existuje dostatečné množství kvalitních, placebem kontrolovaných farmakologických studií, které by umožňovalo dát jednoznačná te- rapeutická doporučení a hlavně vytvořit specifický přístup pro tuto skupinu pacientů. LITERATURA 1. Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson di- sease – epidemiology, mechanisms and management. Nature Reviews Neurology 2012; 8(1): 35. 2. Ashina S, Serrano D, Lipton RB, Maizels M, Manack AN, Turkel CC, Buse DC. Depression and risk of transformation of episodic to chronic migraine. The journal of headache and pain 2012; 13(8): 615–624. 3. Ayerbe L, Ayis S, Crichton SL, Rudd AG, Wolfe CD. Explanatory factors for theincreased mortality of stroke patients with depression. Neurology 2014; 83: 2007–2012. 4. Baskin SM, Smitherman TA. Comorbidity betweenmigraine and depression: update on traditional and alternativetreatments. Neurol Sci 2011; 32(Suppl. 1): 9–13. 5. Boeschoten RE, Braamse AMJ, Beekman ATF, Cuijpers P, van Oppen P, Dekker J, Uitde- haag BMJ. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J. Neurol. Sci 2017; 372: 331–341. 6. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KMA. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology 2003; 60(8): 1308–1312. 7. Brown RG, Jahanshahi M, Marsden CD. Response choice in Parkinson’s disease: the effects of uncertainty and stimulus-response compatibility. Brain 1993; 4: 869–885. 8. Brown RG, Marsden CD, Quinn N, Wyke MA. Alterations in cogni-tive performance and effect-arousal during fluctuations in motor function in Parkinson’s disease. J Neurol Neu- rosurg Psychiatry 1984; 47: 454–46552. 9. Burch R. Antidepressants for preventive treatment of migraine. Current treatment opti- ons in neurology 2019; 21(4): 18. 10. Bužgová R, Hajnová E, Feltl D, Stolička M. Faktory ovlivňující úzkost a depresi u pacientů v konečném stadiu nemoci při hospitalizaci. česká a slovenská Psychiatrie 2014: 110(5): 243–249. 11. Feinstein A, Roy P, Lobaugh N, Feinstein K, O'Connor P, Black S. Structural brain abnor- malities in multiple sclerosis patients with major depression. Neurology 2004; 62: 586–590. 12. Fiest KM, Walker JR, Bernstein CN, Graff LA, Zarychanski R, Abou-Setta AM, Fisk JD. Systema- tic review and meta-analysis of interventions for depression and anxiety in persons with mul- tiple sclerosis. Multiple sclerosis and related disorders 2016; 5: 12–26. 13. Fredrikson S, Cheng Q, Jiang GX, Wasserman D. Elevated suicide risk among patients with multiple sclerosis in Sweden. Neuroepidemiology 2003; 22(2): 146–152. 14. Global Parkinson’s Disease Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 2002; 17: 60–67. 15. Hackett ML, Anderson CS. Predictors of depression after stroke: a systematic review of observational studies. Stroke 2005; 36(10): 2296–2301. 16. Hackett ML, Anderson CS, House A, XIa J. Interventions for treatingd epression after stroke. Cochrane Database Syst Rev 2008; (4): CD003437. 17. Hamelsky SW, Lipton RB. Psychiatric comorbidity of migraine. Headache: The Journal of Head and Face Pain 2006; 46(9): 1327–1333. 18. Herrmann N, Black SE, Lawrence J, Szekely C, Szalai JP. Sunnybrook StrokeStudy: a prospective study of depressive symptoms and functional outcome. Stroke 1998; 29: 618–62. 19. Hung CI, Wang SJ, Yang CH, Liu CY. The impacts of migraine, anxiety disorders, and chronic depression on quality of life in psychiatric outpatients with major depressive di- sorder. J Psychosom Res 2008; 65(2): 135–142. 20. Mills KA, Greene MC, Dezube R, Goodson C, Karmarkar T, Pontone GM. Efficacy and to- lerability of antidepressants in Parkinson's disease: A systematic review and network me- ta-analysis. International journal of geriatric psychiatry 2018; 33(4): 642–651. 21. Mitchell PH, Veith RC, Becker KJ, Buzaitis A, Cain KC, Fruin M, Teri L. Brief psychosocial– behavioral intervention with antidepressant reduces poststroke depression significantly more than usual care with antidepressant: living well with stroke: randomized, controlled trial. Stroke 2009; 40(9): 3073–3078.